DiaMedica Therapeutics Inc. (DMAC) Share-based Payment Arrangement, Expense USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
DiaMedica Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $488 K, a 15.6% increase year-over-year.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $1.75 M, a 8.23% increase year-over-year.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.68 M, a 12.1% increase from 2022.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.5 M, a 3.59% decline from 2021.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.56 M, a 15.5% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $1.75 M $488 K +$66 K +15.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $1.68 M $456 K +$45 K +10.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $1.64 M $425 K +$7 K +1.68% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $1.63 M $380 K +$15 K +4.11% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.62 M $422 K +$114 K +37% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $1.5 M $411 K +$113 K +37.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $1.39 M $418 K +$115 K +38% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $1.27 M $365 K -$81 K -18.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $1.36 M $308 K -$203 K -39.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $1.56 M $298 K -$208 K -41.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $1.77 M $303 K -$205 K -40.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $1.97 M $446 K +$10 K +2.29% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $1.96 M $511 K +$118 K +30% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $1.84 M $506 K +$105 K +26.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 $1.74 M $508 K +$57 K +12.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $1.68 M $436 K +$254 K +140% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $1.43 M $393 K +$263 K +202% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.16 M $401 K +$336 K +517% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 $828 K $451 K +$341 K +310% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $487 K $182 K -$110 K -37.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $597 K $130 K -$23 K -15% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 $620 K $65 K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 $110 K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $292 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $153 K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.